文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

非清髓性MHC不相合骨髓移植治疗小鼠β地中海贫血的双向免疫耐受

Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia.
PubMed 文献 · Blood · 2017-03-28

该研究在小鼠β地中海贫血模型中,采用全淋巴照射(TLI)加兔抗胸腺细胞血清(ATS)的非清髓性预处理,发现加入环磷酰胺(CTX)可显著增加受体髓源性抑制细胞(MDSC)和髓系树突状细胞(MDC)的恢复,并改善植入率和移植物抗宿主病(GVHD),为血红蛋白病MHC不相合骨髓移植提供临床前依据。

要点

  • TLI/ATS/CTX预处理较TLI/ATS显著提高β地中海贫血小鼠的植入率和GVHD控制。
  • CTX加入TLI/ATS可显著增加受体MDSC和MDC的恢复(P < .01)。
  • 过继转移TLI/ATS/CTX预处理受体的MDSC可改善GVHD结肠炎和生存(P < .001)。

核心结论

  • 数据为TLI/ATG/烷化剂方案用于血红蛋白病MHC不相合骨髓移植的临床试验提供临床前支持,并阐明TLI/ATS/CTX增强移植耐受的先天免疫机制。

研究设计与样本

  • 研究为小鼠临床前实验,使用非清髓性预处理TLI/ATS(鼠类临床前等效于抗胸腺细胞球蛋白ATG),在BALB/c→B6致死性GVHD模型和BALB/c供者→β地中海贫血HW-80受者中进行。

主要发现

  • TLI/ATS/CTX预处理后,受体MDSC(P < .01)和MDC(P < .01)的恢复显著增加。
  • 在BALB/c→B6致死性GVHD模型中,过继转移TLI/ATS/CTX预处理受体的MDSC与GVHD结肠炎和生存显著改善(P < .001)、MDSC向表达PD配体的MDC转化以及供者自然调节性T细胞恢复增加(P < .01)相关。
  • 在BALB/c供者→β地中海贫血HW-80受者中,TLI/ATS/CTX相比TLI/ATS、致死或亚致死全身照射/ATS/CTX或CTX/ATS预处理,植入率和GVHD显著改善。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonmyeloablative conditioning using total lymphoid irradiation (TLI) and rabbit antithymocyte serum (ATS) (the murine preclinical equivalent of antithymocyte globulin [ATG]) facilitates immune tolerance after bone marrow transplantation (BMT) across major histocompatibility complex (MHC) disparities and may be a useful strategy for nonmalignant disorders. We previously reported that donor effector T-cell function and graft-versus-host disease (GVHD) are regulated via recipient invariant natural killer T-cell (iNKT) interleukin-4-driven expansion of donor Foxp3+ naturally occurring regulatory T cells (Tregs). This occurs via recipient iNKT- and STAT6-dependent expansion of recipient myeloid dendritic cells (MDCs) that induce contact-dependent expansion of donor Treg through PD-1/PD ligand signaling. After TLI/ATS + BMT, Gr-1lowCD11c+ MDCs and Gr-1highCD11cneg myeloid-derived suppressor cells (MDSCs) were enriched in GVHD target organs. We now report that the recovery of both recipient MDSCs (P < .01) and MDCs (P < .01) is significantly increased when the alkylator cyclophosphamide (CTX) is added to TLI/ATS conditioning. In a BALB/c → B6 lethal GVHD model, adoptive transfer of MDSCs from TLI/ATS/CTX-conditioned recipients is associated with significantly improved GVHD colitis and survival (P < .001), conversion of MDSCs to PD ligand-expressing MDCs, and increased donor naturally occurring Treg recovery (P < .01) compared with control treatment. Using BALB/c donors and β-thalassemic HW-80 recipients, we found significantly improved rates of engraftment and GVHD following TLI/ATS/CTX compared with TLI/ATS, lethal or sublethal total body irradiation/ATS/CTX, or CTX/ATS conditioning. These data provide preclinical support for trials of TLI/ATG/alkylator regimens for MHC-mismatched BMT for hemoglobinopathies. The data also delineate innate immune mechanisms by which TLI/ATS/CTX conditioning may augment transplantation tolerance.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. E S, Seth A, Vogel P, et al. Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia. Blood. 2017. PMID: 28351935. doi:10.1182/blood-2016-03-704387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。